- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16.06. | Edgewise data power rival to BMS and Cytokinetics toward phase 3 | ||
| 16.06. | Merck inks $510M biobucks data generation partnership with Protillion | ||
| 16.06. | Adaptive plots splitting Pfizer-partnered drug discovery unit from diagnostics business | ||
| 15.06. | Spyre spies another edge for UC ambitions with midstage win for anti-TL1A antibody | ||
| 15.06. | Japan, South Korea challenge the West's place in research rankings: report | ||
| 15.06. | Intellia touts 'paradigm-shifting' phase 3 data for one-time HAE treatment | ||
| 15.06. | Amgen loses in Harbour antibody patent case, ordered to pay $20M+ | ||
| 15.06. | Neumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies | ||
| 15.06. | Traws defers midphase flu study after negative regulatory review | ||
| 15.06. | Soligenix axes lymphoma program after phase 3 setback, mulls M&A options | ||
| 12.06. | 'I wouldn't call it a blip': Biotech IPOs here to stay after another record-breaking listing | ||
| 12.06. | Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover | ||
| 11.06. | Fierce Biotech heading to UK to host event amid London Life Sciences Week | ||
| 11.06. | Cardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPO | ||
| 11.06. | Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3 | ||
| 11.06. | Takeda's TYK2 inhibitor beats Bristol Myers' Sotyktu in phase 3 psoriasis showdown | ||
| 10.06. | ADA: Novo's Lange says 'jury still out' on CagriSema amid tough retatrutide comparisons | ||
| 10.06. | Ethyreal Bio manifests with $101M in pack of biotechs gunning for Amgen's Tepezza | ||
| 10.06. | Novartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B | ||
| 10.06. | Cancer-focused Parabilis' upsized $670M IPO breaks new for record for biotechs | ||
| 10.06. | Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue | ||
| 09.06. | Fueled by M&A and partnerships, biotech is poised for continued growth: EY | ||
| 09.06. | Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M | ||
| 09.06. | Lilly moves deeper into Alzheimer's research with AlzeCure licensing deal | ||
| 09.06. | ADA: AstraZeneca's oral GLP-1 shows 'competitive efficacy' in phase 2, setting stage for pivotal program |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.